Compare · INCY vs OABI
INCY vs OABI
Side-by-side comparison of Incyte Corp. (INCY) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $23.42B, about 76.2x OABI ($307.3M).
- INCY has been more active in the news (21 items in the past 4 weeks vs 4 for OABI).
- INCY has more recent analyst coverage (25 ratings vs 5 for OABI).
- Company
- Incyte Corp.
- OmniAb Inc.
- Price
- -
- -
- Market cap
- $23.42B
- $307.3M
- 1M return
- -
- +4.67%
- 1Y return
- -
- +9.23%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 21
- 4
- Recent ratings
- 25
- 5
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Latest INCY
- Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
- President, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 22,919 shares, decreasing direct ownership by 10% to 217,929 units (SEC Form 4) (tax withholding)
- EVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 1,949 shares, decreasing direct ownership by 3% to 57,712 units (SEC Form 4) (tax liability)
- Principal Accounting Officer Tray Thomas covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 9% to 18,865 units (SEC Form 4) to cover withholding tax
- CMO & Head of Late-Stage Dev. Stein Steven H sold $3,192,193 worth of shares (28,237 units at $113.05) and covered exercise/tax liability with 24,918 shares, decreasing direct ownership by 70% to 22,995 units (SEC Form 4) (for tax liability)
- EVP, Head of U.S. Commercial Issa Mohamed Khairie covered exercise/tax liability with 1,099 shares, decreasing direct ownership by 2% to 65,033 units (SEC Form 4) to satisfy withholding tax
- Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
- Incyte to Report Second Quarter Financial Results
- Chief Executive Officer Meury William covered exercise/tax liability with 4,779 shares, decreasing direct ownership by 3% to 156,322 units (SEC Form 4) (withholding tax)
- EVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 350 shares, decreasing direct ownership by 0.58% to 59,661 units (SEC Form 4) to cover taxes
Latest OABI
- OmniAb to Report Second Quarter 2026 Financial Results on August 6
- SEC Form 3 filed by new insider Nwachuku Amechi Ekeke
- OmniAb Inc. filed SEC Form 8-K: Leadership Update
- OmniAb Names Amechi Nwachuku Chief Operating Officer
- Director Bertozzi Carolyn R converted options into 20,000 shares, increasing direct ownership by 21% to 113,308 units (SEC Form 4)
- Director Cochran Jennifer R. converted options into 20,000 shares, increasing direct ownership by 12% to 185,274 units (SEC Form 4)
- Director Crouse Steven C. converted options into 20,000 shares, increasing direct ownership by 150% to 33,333 units (SEC Form 4)
- Director Gotwals Philip J converted options into 20,000 shares, increasing direct ownership by 150% to 33,333 units (SEC Form 4)
- Director Higgins John L converted options into 20,000 shares, increasing direct ownership by 0.68% to 2,962,320 units (SEC Form 4)
- Director Love Steven converted options into 20,000 shares, increasing direct ownership by 28% to 91,666 units (SEC Form 4)